Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Benralizumab, ATC R03DX10 für die Zeit 01.06.2025 - 31.05.2027

Worth a closer look

• § 130a Abs. 8 SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount agreements for medicinal products to be borne by the statutory health insurance funds.
• The DAK-Gesundheit assumes that this procedure does not fall within the scope of cartel procurement law due to a lack of selection decision and thus the non-discriminatory access of all pharmaceutical companies.
• The contract documents are available for download at www.dtvp.de/center
• The offer is to be submitted in text form as an electronic offer per email to openhouse@dak.de.
• The submission of the offer by post is not provided for in this procedure.
• Please do not submit the offer via the German Procurement Portal.
• For the preservation of the deadline, an electronic receipt of the complete documents per email to the email address openhouse@dak.de is sufficient.
• Later entries are possible at any time.
• To join during the term of the contract on the 1st or 15th of the following month, the above documents must be with the DAK-Gesundheit by the 5th of the preceding month.
• The publication is made using the form for open procedures.
• As already clearly stated, this is such a non-exclusive agreement - the notice had to be used for technical reasons as there is no suitable form for approval procedures.